急性失代偿性心力衰竭患者快速心室率心房扑动与心房颤动的管理:一项系统评价
该系统评价纳入5项研究(1项住院场景RCT、4项回顾性研究,其中2项在急诊科、3项在住院场景),评估急性失代偿性心衰合并快速心室率房颤/房扑患者在急诊科、ICU或过渡病房中药理与非药理管理的有效性和安全性。地尔硫䓬 vs 安慰剂的RCT中,治疗组22例(100%)有治疗反应,安慰剂组0/15(0%),两组安全性无显著差异。一项观察性研究显示美托洛尔与地尔硫䓬在成功率控制上无差异,但地尔硫䓬组心衰症状恶化更常见(19例[33%] vs 10例[15%],p=0.019)。仅一项研究纳入电复律(1例失败未转复窦律)。纳入研究总体偏倚风险为严重至临界,结局定义异质性和数据缺失使定量Meta分析无法进行。
要点
- 地尔硫䓬 vs 安慰剂RCT:治疗组22例(100%)有治疗反应,安慰剂组0/15(0%)无反应,两组安全性无显著差异。
- 一项观察性研究:美托洛尔与地尔硫䓬成功率控制无差异,但地尔硫䓬组心衰症状恶化更常见(19例[33%] vs 10例[15%],p=0.019)。
- 仅一项研究纳入电复律作为非药理管理,1例电复律失败未转复窦律。
- 该系统评价仅纳入5项研究(1项RCT、4项回顾性研究),总体偏倚风险为严重至临界。
- 结局定义异质性和数据缺失使定量Meta分析无法进行,急性期AFRVR合并ADHF管理缺乏高级别证据。
适用人群与场景
- 成人急性失代偿性心衰合并快速心室率心房颤动/心房扑动患者,场景为急诊科、ICU或过渡病房。
研究设计与关键结果
- 系统评价共检索到6577篇唯一文献,5项研究符合纳入标准:1项住院场景RCT和4项回顾性研究(2项在急诊科,3项在住院场景)。
- 地尔硫䓬 vs 安慰剂RCT:治疗组22例(100%)有治疗反应,安慰剂组0/15(0%)有治疗反应,两组间无显著安全性差异。
- 一项观察性研究显示美托洛尔与地尔硫䓬在成功率控制方面无差异,但接受地尔硫䓬者心衰症状恶化更常见(19例[33%] vs 10例[15%],p=0.019)。
- 一项研究纳入电复律作为非药理管理,1例接受电复律者未能转复窦性心律。
- 三项观察性研究数据有限。
- 纳入研究总体偏倚风险为严重至临界。
- 有效性和安全性结局定义的异质性及数据缺失使结果无法进行定量Meta分析合并。
证据类型、等级与局限
- 证据类型:系统评价,纳入1项随机对照试验和4项回顾性研究。
- 纳入研究总体偏倚风险为严重至临界。
- 有效性和安全性结局定义的异质性及数据缺失使结果无法进行定量Meta分析合并。
- 局限:缺乏高级别证据以指导急性诊疗场景下急性失代偿性心衰患者快速心室率房颤/房扑的有效且安全管理决策。
对床旁实践的改变
- 该系统评价未提供足以改变急诊或ICU床旁实践的高级别证据,原文结论为缺乏指导临床决策的高级别证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective was to evaluate the comparative effectiveness and safety of pharmacological and nonpharmacological management options for atrial fibrillation/atrial flutter with rapid ventricular response (AFRVR) in patients with acute decompensated heart failure (ADHF) in the acute care setting.
METHODS: This study was a systematic review of observational studies or randomized clinical trials (RCT) of adult patients with AFRVR and concomitant ADHF in the emergency department (ED), intensive care unit, or step-down unit. The primary effectiveness outcome was successful rate or rhythm control. Safety outcomes were adverse events, such as symptomatic hypotension and venous thromboembolism.
RESULTS: A total of 6577 unique articles were identified. Five studies met inclusion criteria: one RCT in the inpatient setting and four retrospective studies, two in the ED and the other three in the inpatient setting. In the RCT of diltiazem versus placebo, 22 patients (100%) in the treatment group had a therapeutic response compared to 0/15 (0%) in the placebo group, with no significant safety differences between the two groups. For three of the observational studies, data were limited. One observation study showed no difference between metoprolol and diltiazem for successful rate control, but worsening heart failure symptoms occurred more frequently in those receiving diltiazem compared to metoprolol (19 patients [33%] vs. 10 patients [15%], p = 0.019). A single study included electrical cardioversion (one patient exposed with failure to convert to sinus rhythm) as nonpharmacological management. The overall risk of bias for included studies ranged from serious to critical. Missing data and heterogeneity of definitions for effectiveness and safety outcomes precluded the combination of results for quantitative meta-analysis.
CONCLUSIONS: High-level evidence to inform clinical decision making regarding effective and safe management of AFRVR in patients with ADHF in the acute care setting is lacking.
参考来源
- Niforatos JD, Ehmann MR, Balhara KS, et al. Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. Acad Emerg Med. 2022. PMID: 36326565. doi:10.1111/acem.14618
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。